profit from every $100 of sales.
$0$100
Palatin Technologies
$6.23-5.18% today
-42.3% in 1 year
1-year low $4.771-year high $28.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Palatin Technologies sold, what it kept, and what it did with the cash.
Sales went from $1.47 million in 2022 to $0 in 2025, with -$17.3 million of profit last year.
SalesProfit
Palatin Technologies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Palatin Technologies | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Palatin Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 5 | 4 | 0 | |
| 1 | 4 | 4 | 0 | |
| -37 | -33 | -30 | -23 | |
| -36 | -28 | -29 | -17 | |
| -36 | -24 | -30 | -17 | |
| -189.50 | -110.50 | -101.16 | -32.15 | |
| 85.2% | 91.4% | 97.8% | – | |
| -2,491.6% | -689.9% | -674.3% | – | |
| -2,465.1% | -495.2% | -662.3% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 36 | 18 | 11 | 3 |
| Cash | 30 | 8 | 10 | 3 |
| Total debt | 1 | 1 | 1 | 0 |
| Total liabilities | 20 | 20 | 11 | 8 |
| 16 | -2 | -0 | -5 | |
| 0 | 0 | 0 | 1 | |
| -164.0% | – | -4,903.1% | – | |
| -222.5% | 1,214.1% | 26,669.9% | 362.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -30 | -29 | -31 | -21 | |
| 0 | 0 | 0 | – | |
| -30 | -30 | -32 | -21 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 2 | 2 | 1 |
Valuation
- –
- 3.3×
- –
- 5.3×
- 2.5×
- –
- –
- -283.9%
- -268.0%
- 0.0%
Profitability
- 97.8%
- -674.3%
- -662.3%
- -67.9%
- -81.4%
- -704.3%
- -141.4%
- -47.3%
- -82.8%
- 95.7%
Growth
- +74.9%
- –
- +32.4%
- –
- −51.2%
Financial health
- -0.3×
- 0.03
- 2.2%
- -1,220.0×
- 5.04
- 5.04
- 0.97
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Top 8%of 886
What analysts expect
- Average price target
- $55.00
- Range
- $50.00 – $60.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.37 | -1.24 | +70.2% |
| Feb 17, 2026 | -2.86 | -2.35 | −21.5% |
| Nov 14, 2025 | 4.26 | – | – |
| Sep 23, 2025 | -4.14 | -9.50 | +56.4% |
| May 14, 2025 | -9.00 | -0.17 | −5,194.1% |
| Feb 13, 2025 | -0.12 | -0.42 | +71.4% |
| Oct 1, 2024 | -0.51 | -0.55 | +7.3% |
| Sep 30, 2024 | -0.49 | -0.56 | +12.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
68Pass
Benjamin Graham
45No pass
Philip Fisher
69Pass
Peter Lynch
100Pass
Joel Greenblatt
2No pass
Charlie Munger
67Pass
Terry Smith
68Pass
Questions about Palatin Technologies
Is Palatin Technologies a good stock to buy?
A business with weak numbers that is not profitable yet. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Palatin Technologies AI analysis
What does Palatin Technologies do?
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. It is in Biotechnology.
Does Palatin Technologies pay a dividend?
No. Palatin Technologies does not pay a dividend at the moment.
Is Palatin Technologies stock halal?
Yes. Palatin Technologies passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Palatin Technologies stock done over the past year?
Down 42.3% over the past twelve months, to $6.23. It traded between $4.77 and $28.00 and is 77.8% below its high.
Who are Palatin Technologies's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Palatin Technologies's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.